Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in CRSwNP With Comorbid Eosinophilic Otitis Media
2023-508068-31-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic otitis media (EOM) (2 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoint: Change in otologic questionnaire scores. Planned start Aug 2024; status: authorised.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)eosinophilic otitis media (EOM)
Beyond the preview
Go deeper on 2023-508068-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508068-31-00.